Shenzhen Kangzhe Pharmaceutical Co., Ltd.

2 in Phase 3

Quick facts

Phase 3 pipeline

Gan Fu Le Tablets · Hepatology
Gan Fu Le Tablets is a traditional Chinese medicine formulation designed to support liver function and promote hepatic health.
Tyroserleutide for injection · Diabetes
Tyroserleutide for injection is a recombinant human proinsulin-derived peptide that mimics the action of incretin hormones to enhance glucose-dependent insulin secretion.

Phase 2 pipeline

mitomycin, Fluorouracil
Mucopolysaccharide Polysulfate Cream
Mucopolysaccharide Polysulfate Cream and glucocorticoids · Dermatology, Immunology, Gastroenterology
Glucocorticoids exert their effects by binding to the glucocorticoid receptor (GR) in the cytoplasm, which then translocates to the nucleus and regulates gene expression.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Shenzhen Kangzhe Pharmaceutical Co., Ltd.

What is Shenzhen Kangzhe Pharmaceutical Co., Ltd.'s pipeline?

Shenzhen Kangzhe Pharmaceutical Co., Ltd. has 2 drugs in Phase 3, 3 in Phase 2, 0 in Phase 1. Late-stage candidates include Gan Fu Le Tablets, Tyroserleutide for injection.

Sector hub: All tracked pharma companies